nodes	percent_of_prediction	percent_of_DWPC	metapath
Dipyridamole—ABCC4—Conjugated Estrogens—prostate cancer	0.0763	0.303	CbGbCtD
Dipyridamole—ABCB1—Estramustine—prostate cancer	0.0351	0.139	CbGbCtD
Dipyridamole—ABCB1—Cabazitaxel—prostate cancer	0.0231	0.0919	CbGbCtD
Dipyridamole—ABCB1—Estrone—prostate cancer	0.0226	0.0898	CbGbCtD
Dipyridamole—ABCB1—Ethinyl Estradiol—prostate cancer	0.0202	0.0801	CbGbCtD
Dipyridamole—ABCB1—Conjugated Estrogens—prostate cancer	0.0148	0.0588	CbGbCtD
Dipyridamole—ABCB1—Mitoxantrone—prostate cancer	0.0135	0.0534	CbGbCtD
Dipyridamole—ABCB1—Estradiol—prostate cancer	0.013	0.0516	CbGbCtD
Dipyridamole—ABCB1—Prednisone—prostate cancer	0.0112	0.0444	CbGbCtD
Dipyridamole—ABCB1—Etoposide—prostate cancer	0.00848	0.0337	CbGbCtD
Dipyridamole—ABCB1—Docetaxel—prostate cancer	0.00776	0.0308	CbGbCtD
Dipyridamole—PDE5A—penis—prostate cancer	0.00753	0.0462	CbGeAlD
Dipyridamole—PDE3A—penis—prostate cancer	0.00732	0.045	CbGeAlD
Dipyridamole—PDE1C—prostate gland—prostate cancer	0.00593	0.0364	CbGeAlD
Dipyridamole—ABCB1—Doxorubicin—prostate cancer	0.00579	0.023	CbGbCtD
Dipyridamole—PRUNE—prostate gland—prostate cancer	0.00535	0.0329	CbGeAlD
Dipyridamole—PDE6D—prostate gland—prostate cancer	0.00517	0.0317	CbGeAlD
Dipyridamole—PDE6B—prostate gland—prostate cancer	0.00508	0.0312	CbGeAlD
Dipyridamole—PDE11A—prostate gland—prostate cancer	0.00473	0.029	CbGeAlD
Dipyridamole—PRUNE—Podofilox—Etoposide—prostate cancer	0.00386	1	CbGdCrCtD
Dipyridamole—PDE6A—testis—prostate cancer	0.00373	0.0229	CbGeAlD
Dipyridamole—PDE7B—prostate gland—prostate cancer	0.00368	0.0226	CbGeAlD
Dipyridamole—PDE11A—epithelium—prostate cancer	0.00347	0.0213	CbGeAlD
Dipyridamole—PDE2A—prostate gland—prostate cancer	0.00307	0.0189	CbGeAlD
Dipyridamole—PDE10A—prostate gland—prostate cancer	0.00307	0.0189	CbGeAlD
Dipyridamole—PDE1B—prostate gland—prostate cancer	0.00305	0.0187	CbGeAlD
Dipyridamole—PDE8B—prostate gland—prostate cancer	0.00293	0.018	CbGeAlD
Dipyridamole—PDE7A—renal system—prostate cancer	0.00287	0.0176	CbGeAlD
Dipyridamole—PDE3B—prostate gland—prostate cancer	0.00286	0.0176	CbGeAlD
Dipyridamole—PDE6D—bone marrow—prostate cancer	0.00266	0.0164	CbGeAlD
Dipyridamole—PDE8A—prostate gland—prostate cancer	0.00264	0.0162	CbGeAlD
Dipyridamole—PDE1C—testis—prostate cancer	0.00261	0.016	CbGeAlD
Dipyridamole—PDE2A—seminal vesicle—prostate cancer	0.0026	0.016	CbGeAlD
Dipyridamole—PDE1A—prostate gland—prostate cancer	0.00255	0.0157	CbGeAlD
Dipyridamole—PRUNE—testis—prostate cancer	0.00236	0.0145	CbGeAlD
Dipyridamole—PDE6D—testis—prostate cancer	0.00228	0.014	CbGeAlD
Dipyridamole—PDE6B—testis—prostate cancer	0.00224	0.0138	CbGeAlD
Dipyridamole—PDE8A—seminal vesicle—prostate cancer	0.00223	0.0137	CbGeAlD
Dipyridamole—ADA—prostate gland—prostate cancer	0.00217	0.0133	CbGeAlD
Dipyridamole—PDE4A—prostate gland—prostate cancer	0.00211	0.013	CbGeAlD
Dipyridamole—PDE11A—testis—prostate cancer	0.00208	0.0128	CbGeAlD
Dipyridamole—PDE2A—urethra—prostate cancer	0.00206	0.0126	CbGeAlD
Dipyridamole—PDE6G—testis—prostate cancer	0.002	0.0123	CbGeAlD
Dipyridamole—PDE1C—lymph node—prostate cancer	0.00189	0.0116	CbGeAlD
Dipyridamole—PDE5A—prostate gland—prostate cancer	0.0018	0.011	CbGeAlD
Dipyridamole—PDE8A—urethra—prostate cancer	0.00177	0.0108	CbGeAlD
Dipyridamole—PDE3A—prostate gland—prostate cancer	0.00175	0.0107	CbGeAlD
Dipyridamole—PDE1A—renal system—prostate cancer	0.00174	0.0107	CbGeAlD
Dipyridamole—PRUNE—lymph node—prostate cancer	0.00171	0.0105	CbGeAlD
Dipyridamole—PDE6D—lymph node—prostate cancer	0.00165	0.0101	CbGeAlD
Dipyridamole—ABCC5—prostate gland—prostate cancer	0.00164	0.0101	CbGeAlD
Dipyridamole—PDE7B—testis—prostate cancer	0.00162	0.00996	CbGeAlD
Dipyridamole—SLC29A1—prostate gland—prostate cancer	0.00151	0.00927	CbGeAlD
Dipyridamole—ADA—renal system—prostate cancer	0.00148	0.00908	CbGeAlD
Dipyridamole—PDE3B—bone marrow—prostate cancer	0.00148	0.00906	CbGeAlD
Dipyridamole—PDE6G—lymph node—prostate cancer	0.00145	0.00892	CbGeAlD
Dipyridamole—PDE2A—testis—prostate cancer	0.00135	0.00831	CbGeAlD
Dipyridamole—PDE10A—testis—prostate cancer	0.00135	0.00831	CbGeAlD
Dipyridamole—PDE1B—testis—prostate cancer	0.00134	0.00824	CbGeAlD
Dipyridamole—PDE5A—epithelium—prostate cancer	0.00132	0.00812	CbGeAlD
Dipyridamole—PDE8B—testis—prostate cancer	0.00129	0.00793	CbGeAlD
Dipyridamole—PDE3B—testis—prostate cancer	0.00126	0.00775	CbGeAlD
Dipyridamole—PDE5A—renal system—prostate cancer	0.00123	0.00753	CbGeAlD
Dipyridamole—PDE5A—urethra—prostate cancer	0.0012	0.00739	CbGeAlD
Dipyridamole—PDE7B—lymph node—prostate cancer	0.00118	0.00722	CbGeAlD
Dipyridamole—PDE8A—testis—prostate cancer	0.00116	0.00714	CbGeAlD
Dipyridamole—ABCC4—prostate gland—prostate cancer	0.00114	0.007	CbGeAlD
Dipyridamole—PDE1A—testis—prostate cancer	0.00112	0.00691	CbGeAlD
Dipyridamole—ADA—bone marrow—prostate cancer	0.00112	0.00687	CbGeAlD
Dipyridamole—SLC29A1—renal system—prostate cancer	0.00103	0.00632	CbGeAlD
Dipyridamole—SLC29A1—urethra—prostate cancer	0.00101	0.00621	CbGeAlD
Dipyridamole—PDE2A—lymph node—prostate cancer	0.000981	0.00603	CbGeAlD
Dipyridamole—PDE10A—lymph node—prostate cancer	0.000981	0.00603	CbGeAlD
Dipyridamole—PDE1B—lymph node—prostate cancer	0.000973	0.00597	CbGeAlD
Dipyridamole—ADA—testis—prostate cancer	0.000956	0.00587	CbGeAlD
Dipyridamole—PDE8B—lymph node—prostate cancer	0.000936	0.00575	CbGeAlD
Dipyridamole—PDE4A—testis—prostate cancer	0.000932	0.00572	CbGeAlD
Dipyridamole—PDE3B—lymph node—prostate cancer	0.000914	0.00562	CbGeAlD
Dipyridamole—ABCC5—bone marrow—prostate cancer	0.000848	0.00521	CbGeAlD
Dipyridamole—PDE8A—lymph node—prostate cancer	0.000842	0.00517	CbGeAlD
Dipyridamole—PDE1A—lymph node—prostate cancer	0.000815	0.00501	CbGeAlD
Dipyridamole—PDE5A—testis—prostate cancer	0.000792	0.00487	CbGeAlD
Dipyridamole—SLC29A1—bone marrow—prostate cancer	0.000778	0.00478	CbGeAlD
Dipyridamole—ABCC4—renal system—prostate cancer	0.000777	0.00477	CbGeAlD
Dipyridamole—PDE3A—testis—prostate cancer	0.000771	0.00473	CbGeAlD
Dipyridamole—ABCC5—testis—prostate cancer	0.000725	0.00445	CbGeAlD
Dipyridamole—ADA—lymph node—prostate cancer	0.000693	0.00426	CbGeAlD
Dipyridamole—PDE4A—lymph node—prostate cancer	0.000675	0.00415	CbGeAlD
Dipyridamole—SLC29A1—testis—prostate cancer	0.000665	0.00409	CbGeAlD
Dipyridamole—ABCC4—bone marrow—prostate cancer	0.000587	0.00361	CbGeAlD
Dipyridamole—PDE5A—lymph node—prostate cancer	0.000574	0.00353	CbGeAlD
Dipyridamole—PDE3A—lymph node—prostate cancer	0.000559	0.00343	CbGeAlD
Dipyridamole—ABCC5—lymph node—prostate cancer	0.000525	0.00323	CbGeAlD
Dipyridamole—ABCC4—testis—prostate cancer	0.000502	0.00308	CbGeAlD
Dipyridamole—SLC29A1—lymph node—prostate cancer	0.000482	0.00296	CbGeAlD
Dipyridamole—ABCB1—prostate gland—prostate cancer	0.000397	0.00244	CbGeAlD
Dipyridamole—ABCC4—lymph node—prostate cancer	0.000364	0.00224	CbGeAlD
Dipyridamole—ABCB1—seminal vesicle—prostate cancer	0.000336	0.00206	CbGeAlD
Dipyridamole—ABCB1—epithelium—prostate cancer	0.000292	0.00179	CbGeAlD
Dipyridamole—ABCB1—renal system—prostate cancer	0.00027	0.00166	CbGeAlD
Dipyridamole—ABCB1—urethra—prostate cancer	0.000266	0.00163	CbGeAlD
Dipyridamole—ABCB1—bone marrow—prostate cancer	0.000204	0.00126	CbGeAlD
Dipyridamole—ABCB1—testis—prostate cancer	0.000175	0.00107	CbGeAlD
Dipyridamole—ABCB1—lymph node—prostate cancer	0.000127	0.000778	CbGeAlD
Dipyridamole—Anaemia—Prednisone—prostate cancer	9.43e-05	0.000313	CcSEcCtD
Dipyridamole—Tachycardia—Docetaxel—prostate cancer	9.42e-05	0.000313	CcSEcCtD
Dipyridamole—Headache—Estradiol—prostate cancer	9.39e-05	0.000312	CcSEcCtD
Dipyridamole—Skin disorder—Docetaxel—prostate cancer	9.38e-05	0.000311	CcSEcCtD
Dipyridamole—Oedema—Capecitabine—prostate cancer	9.34e-05	0.00031	CcSEcCtD
Dipyridamole—Bradycardia—Epirubicin—prostate cancer	9.33e-05	0.00031	CcSEcCtD
Dipyridamole—Angioedema—Prednisone—prostate cancer	9.32e-05	0.00031	CcSEcCtD
Dipyridamole—Urticaria—Etoposide—prostate cancer	9.23e-05	0.000306	CcSEcCtD
Dipyridamole—Haemoglobin—Epirubicin—prostate cancer	9.21e-05	0.000306	CcSEcCtD
Dipyridamole—Malaise—Prednisone—prostate cancer	9.2e-05	0.000305	CcSEcCtD
Dipyridamole—Shock—Capecitabine—prostate cancer	9.19e-05	0.000305	CcSEcCtD
Dipyridamole—Rhinitis—Epirubicin—prostate cancer	9.19e-05	0.000305	CcSEcCtD
Dipyridamole—Abdominal pain—Etoposide—prostate cancer	9.18e-05	0.000305	CcSEcCtD
Dipyridamole—Nervous system disorder—Capecitabine—prostate cancer	9.16e-05	0.000304	CcSEcCtD
Dipyridamole—Vertigo—Prednisone—prostate cancer	9.16e-05	0.000304	CcSEcCtD
Dipyridamole—Hepatitis—Epirubicin—prostate cancer	9.16e-05	0.000304	CcSEcCtD
Dipyridamole—Haemorrhage—Epirubicin—prostate cancer	9.16e-05	0.000304	CcSEcCtD
Dipyridamole—Thrombocytopenia—Capecitabine—prostate cancer	9.15e-05	0.000304	CcSEcCtD
Dipyridamole—Syncope—Prednisone—prostate cancer	9.15e-05	0.000304	CcSEcCtD
Dipyridamole—Tachycardia—Capecitabine—prostate cancer	9.12e-05	0.000303	CcSEcCtD
Dipyridamole—Hypoaesthesia—Epirubicin—prostate cancer	9.12e-05	0.000303	CcSEcCtD
Dipyridamole—Pharyngitis—Epirubicin—prostate cancer	9.09e-05	0.000302	CcSEcCtD
Dipyridamole—Skin disorder—Capecitabine—prostate cancer	9.08e-05	0.000301	CcSEcCtD
Dipyridamole—Hyperhidrosis—Capecitabine—prostate cancer	9.03e-05	0.0003	CcSEcCtD
Dipyridamole—Hypotension—Docetaxel—prostate cancer	9.02e-05	0.0003	CcSEcCtD
Dipyridamole—Loss of consciousness—Prednisone—prostate cancer	8.96e-05	0.000298	CcSEcCtD
Dipyridamole—Nausea—Estradiol—prostate cancer	8.9e-05	0.000296	CcSEcCtD
Dipyridamole—Vomiting—Mitoxantrone—prostate cancer	8.88e-05	0.000295	CcSEcCtD
Dipyridamole—Convulsion—Prednisone—prostate cancer	8.84e-05	0.000293	CcSEcCtD
Dipyridamole—Hypertension—Prednisone—prostate cancer	8.81e-05	0.000292	CcSEcCtD
Dipyridamole—Rash—Mitoxantrone—prostate cancer	8.8e-05	0.000292	CcSEcCtD
Dipyridamole—Dermatitis—Mitoxantrone—prostate cancer	8.8e-05	0.000292	CcSEcCtD
Dipyridamole—Musculoskeletal discomfort—Docetaxel—prostate cancer	8.79e-05	0.000292	CcSEcCtD
Dipyridamole—Headache—Mitoxantrone—prostate cancer	8.75e-05	0.000291	CcSEcCtD
Dipyridamole—Hypotension—Capecitabine—prostate cancer	8.73e-05	0.00029	CcSEcCtD
Dipyridamole—Arthralgia—Prednisone—prostate cancer	8.68e-05	0.000288	CcSEcCtD
Dipyridamole—Myalgia—Prednisone—prostate cancer	8.68e-05	0.000288	CcSEcCtD
Dipyridamole—Paraesthesia—Docetaxel—prostate cancer	8.67e-05	0.000288	CcSEcCtD
Dipyridamole—Anxiety—Prednisone—prostate cancer	8.65e-05	0.000287	CcSEcCtD
Dipyridamole—Bradycardia—Doxorubicin—prostate cancer	8.63e-05	0.000287	CcSEcCtD
Dipyridamole—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	8.62e-05	0.000286	CcSEcCtD
Dipyridamole—Dyspnoea—Docetaxel—prostate cancer	8.61e-05	0.000286	CcSEcCtD
Dipyridamole—Somnolence—Docetaxel—prostate cancer	8.58e-05	0.000285	CcSEcCtD
Dipyridamole—Discomfort—Prednisone—prostate cancer	8.58e-05	0.000285	CcSEcCtD
Dipyridamole—Hypersensitivity—Etoposide—prostate cancer	8.56e-05	0.000284	CcSEcCtD
Dipyridamole—Tinnitus—Epirubicin—prostate cancer	8.54e-05	0.000284	CcSEcCtD
Dipyridamole—Haemoglobin—Doxorubicin—prostate cancer	8.52e-05	0.000283	CcSEcCtD
Dipyridamole—Musculoskeletal discomfort—Capecitabine—prostate cancer	8.51e-05	0.000283	CcSEcCtD
Dipyridamole—Flushing—Epirubicin—prostate cancer	8.5e-05	0.000282	CcSEcCtD
Dipyridamole—Cardiac disorder—Epirubicin—prostate cancer	8.5e-05	0.000282	CcSEcCtD
Dipyridamole—Rhinitis—Doxorubicin—prostate cancer	8.5e-05	0.000282	CcSEcCtD
Dipyridamole—Dyspepsia—Docetaxel—prostate cancer	8.5e-05	0.000282	CcSEcCtD
Dipyridamole—Hepatitis—Doxorubicin—prostate cancer	8.48e-05	0.000282	CcSEcCtD
Dipyridamole—Haemorrhage—Doxorubicin—prostate cancer	8.48e-05	0.000282	CcSEcCtD
Dipyridamole—Hypoaesthesia—Doxorubicin—prostate cancer	8.44e-05	0.00028	CcSEcCtD
Dipyridamole—Pharyngitis—Doxorubicin—prostate cancer	8.42e-05	0.000279	CcSEcCtD
Dipyridamole—Paraesthesia—Capecitabine—prostate cancer	8.39e-05	0.000279	CcSEcCtD
Dipyridamole—Gastrointestinal disorder—Docetaxel—prostate cancer	8.33e-05	0.000277	CcSEcCtD
Dipyridamole—Asthenia—Etoposide—prostate cancer	8.33e-05	0.000277	CcSEcCtD
Dipyridamole—Dyspnoea—Capecitabine—prostate cancer	8.33e-05	0.000277	CcSEcCtD
Dipyridamole—Anaphylactic shock—Prednisone—prostate cancer	8.32e-05	0.000276	CcSEcCtD
Dipyridamole—Oedema—Prednisone—prostate cancer	8.32e-05	0.000276	CcSEcCtD
Dipyridamole—Fatigue—Docetaxel—prostate cancer	8.32e-05	0.000276	CcSEcCtD
Dipyridamole—Angiopathy—Epirubicin—prostate cancer	8.31e-05	0.000276	CcSEcCtD
Dipyridamole—Nausea—Mitoxantrone—prostate cancer	8.29e-05	0.000275	CcSEcCtD
Dipyridamole—Immune system disorder—Epirubicin—prostate cancer	8.28e-05	0.000275	CcSEcCtD
Dipyridamole—Mediastinal disorder—Epirubicin—prostate cancer	8.26e-05	0.000274	CcSEcCtD
Dipyridamole—Pain—Docetaxel—prostate cancer	8.25e-05	0.000274	CcSEcCtD
Dipyridamole—Dyspepsia—Capecitabine—prostate cancer	8.23e-05	0.000273	CcSEcCtD
Dipyridamole—Chills—Epirubicin—prostate cancer	8.22e-05	0.000273	CcSEcCtD
Dipyridamole—Pruritus—Etoposide—prostate cancer	8.22e-05	0.000273	CcSEcCtD
Dipyridamole—Shock—Prednisone—prostate cancer	8.19e-05	0.000272	CcSEcCtD
Dipyridamole—Arrhythmia—Epirubicin—prostate cancer	8.19e-05	0.000272	CcSEcCtD
Dipyridamole—Nervous system disorder—Prednisone—prostate cancer	8.16e-05	0.000271	CcSEcCtD
Dipyridamole—Tachycardia—Prednisone—prostate cancer	8.12e-05	0.00027	CcSEcCtD
Dipyridamole—Alopecia—Epirubicin—prostate cancer	8.1e-05	0.000269	CcSEcCtD
Dipyridamole—Skin disorder—Prednisone—prostate cancer	8.09e-05	0.000269	CcSEcCtD
Dipyridamole—Gastrointestinal disorder—Capecitabine—prostate cancer	8.07e-05	0.000268	CcSEcCtD
Dipyridamole—Fatigue—Capecitabine—prostate cancer	8.06e-05	0.000268	CcSEcCtD
Dipyridamole—Hyperhidrosis—Prednisone—prostate cancer	8.05e-05	0.000267	CcSEcCtD
Dipyridamole—Pain—Capecitabine—prostate cancer	7.99e-05	0.000265	CcSEcCtD
Dipyridamole—Feeling abnormal—Docetaxel—prostate cancer	7.95e-05	0.000264	CcSEcCtD
Dipyridamole—Diarrhoea—Etoposide—prostate cancer	7.95e-05	0.000264	CcSEcCtD
Dipyridamole—Tinnitus—Doxorubicin—prostate cancer	7.91e-05	0.000263	CcSEcCtD
Dipyridamole—Gastrointestinal pain—Docetaxel—prostate cancer	7.89e-05	0.000262	CcSEcCtD
Dipyridamole—Flushing—Doxorubicin—prostate cancer	7.87e-05	0.000261	CcSEcCtD
Dipyridamole—Cardiac disorder—Doxorubicin—prostate cancer	7.87e-05	0.000261	CcSEcCtD
Dipyridamole—Flatulence—Epirubicin—prostate cancer	7.86e-05	0.000261	CcSEcCtD
Dipyridamole—Tension—Epirubicin—prostate cancer	7.83e-05	0.00026	CcSEcCtD
Dipyridamole—Dysgeusia—Epirubicin—prostate cancer	7.81e-05	0.000259	CcSEcCtD
Dipyridamole—Nervousness—Epirubicin—prostate cancer	7.75e-05	0.000257	CcSEcCtD
Dipyridamole—Back pain—Epirubicin—prostate cancer	7.72e-05	0.000256	CcSEcCtD
Dipyridamole—Feeling abnormal—Capecitabine—prostate cancer	7.7e-05	0.000256	CcSEcCtD
Dipyridamole—Angiopathy—Doxorubicin—prostate cancer	7.69e-05	0.000255	CcSEcCtD
Dipyridamole—Dizziness—Etoposide—prostate cancer	7.68e-05	0.000255	CcSEcCtD
Dipyridamole—Muscle spasms—Epirubicin—prostate cancer	7.67e-05	0.000255	CcSEcCtD
Dipyridamole—Immune system disorder—Doxorubicin—prostate cancer	7.66e-05	0.000254	CcSEcCtD
Dipyridamole—Gastrointestinal pain—Capecitabine—prostate cancer	7.64e-05	0.000254	CcSEcCtD
Dipyridamole—Mediastinal disorder—Doxorubicin—prostate cancer	7.64e-05	0.000254	CcSEcCtD
Dipyridamole—Abdominal pain—Docetaxel—prostate cancer	7.63e-05	0.000253	CcSEcCtD
Dipyridamole—Chills—Doxorubicin—prostate cancer	7.61e-05	0.000253	CcSEcCtD
Dipyridamole—Musculoskeletal discomfort—Prednisone—prostate cancer	7.58e-05	0.000252	CcSEcCtD
Dipyridamole—Arrhythmia—Doxorubicin—prostate cancer	7.57e-05	0.000252	CcSEcCtD
Dipyridamole—Alopecia—Doxorubicin—prostate cancer	7.49e-05	0.000249	CcSEcCtD
Dipyridamole—Paraesthesia—Prednisone—prostate cancer	7.47e-05	0.000248	CcSEcCtD
Dipyridamole—Urticaria—Capecitabine—prostate cancer	7.42e-05	0.000247	CcSEcCtD
Dipyridamole—Ill-defined disorder—Epirubicin—prostate cancer	7.4e-05	0.000246	CcSEcCtD
Dipyridamole—Abdominal pain—Capecitabine—prostate cancer	7.39e-05	0.000245	CcSEcCtD
Dipyridamole—Vomiting—Etoposide—prostate cancer	7.38e-05	0.000245	CcSEcCtD
Dipyridamole—Anaemia—Epirubicin—prostate cancer	7.37e-05	0.000245	CcSEcCtD
Dipyridamole—Dyspepsia—Prednisone—prostate cancer	7.33e-05	0.000243	CcSEcCtD
Dipyridamole—Rash—Etoposide—prostate cancer	7.32e-05	0.000243	CcSEcCtD
Dipyridamole—Dermatitis—Etoposide—prostate cancer	7.32e-05	0.000243	CcSEcCtD
Dipyridamole—Headache—Etoposide—prostate cancer	7.28e-05	0.000242	CcSEcCtD
Dipyridamole—Flatulence—Doxorubicin—prostate cancer	7.27e-05	0.000242	CcSEcCtD
Dipyridamole—Tension—Doxorubicin—prostate cancer	7.24e-05	0.000241	CcSEcCtD
Dipyridamole—Dysgeusia—Doxorubicin—prostate cancer	7.23e-05	0.00024	CcSEcCtD
Dipyridamole—Malaise—Epirubicin—prostate cancer	7.19e-05	0.000239	CcSEcCtD
Dipyridamole—Fatigue—Prednisone—prostate cancer	7.18e-05	0.000238	CcSEcCtD
Dipyridamole—Nervousness—Doxorubicin—prostate cancer	7.17e-05	0.000238	CcSEcCtD
Dipyridamole—Vertigo—Epirubicin—prostate cancer	7.17e-05	0.000238	CcSEcCtD
Dipyridamole—Syncope—Epirubicin—prostate cancer	7.15e-05	0.000238	CcSEcCtD
Dipyridamole—Back pain—Doxorubicin—prostate cancer	7.14e-05	0.000237	CcSEcCtD
Dipyridamole—Hypersensitivity—Docetaxel—prostate cancer	7.11e-05	0.000236	CcSEcCtD
Dipyridamole—Muscle spasms—Doxorubicin—prostate cancer	7.1e-05	0.000236	CcSEcCtD
Dipyridamole—Palpitations—Epirubicin—prostate cancer	7.05e-05	0.000234	CcSEcCtD
Dipyridamole—Loss of consciousness—Epirubicin—prostate cancer	7.01e-05	0.000233	CcSEcCtD
Dipyridamole—Cough—Epirubicin—prostate cancer	6.96e-05	0.000231	CcSEcCtD
Dipyridamole—Asthenia—Docetaxel—prostate cancer	6.93e-05	0.00023	CcSEcCtD
Dipyridamole—Convulsion—Epirubicin—prostate cancer	6.91e-05	0.00023	CcSEcCtD
Dipyridamole—Nausea—Etoposide—prostate cancer	6.9e-05	0.000229	CcSEcCtD
Dipyridamole—Hypertension—Epirubicin—prostate cancer	6.89e-05	0.000229	CcSEcCtD
Dipyridamole—Hypersensitivity—Capecitabine—prostate cancer	6.89e-05	0.000229	CcSEcCtD
Dipyridamole—Feeling abnormal—Prednisone—prostate cancer	6.86e-05	0.000228	CcSEcCtD
Dipyridamole—Ill-defined disorder—Doxorubicin—prostate cancer	6.85e-05	0.000227	CcSEcCtD
Dipyridamole—Pruritus—Docetaxel—prostate cancer	6.83e-05	0.000227	CcSEcCtD
Dipyridamole—Anaemia—Doxorubicin—prostate cancer	6.82e-05	0.000227	CcSEcCtD
Dipyridamole—Gastrointestinal pain—Prednisone—prostate cancer	6.81e-05	0.000226	CcSEcCtD
Dipyridamole—Arthralgia—Epirubicin—prostate cancer	6.79e-05	0.000226	CcSEcCtD
Dipyridamole—Chest pain—Epirubicin—prostate cancer	6.79e-05	0.000226	CcSEcCtD
Dipyridamole—Myalgia—Epirubicin—prostate cancer	6.79e-05	0.000226	CcSEcCtD
Dipyridamole—Anxiety—Epirubicin—prostate cancer	6.77e-05	0.000225	CcSEcCtD
Dipyridamole—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	6.74e-05	0.000224	CcSEcCtD
Dipyridamole—Discomfort—Epirubicin—prostate cancer	6.71e-05	0.000223	CcSEcCtD
Dipyridamole—Asthenia—Capecitabine—prostate cancer	6.7e-05	0.000223	CcSEcCtD
Dipyridamole—Malaise—Doxorubicin—prostate cancer	6.66e-05	0.000221	CcSEcCtD
Dipyridamole—Dry mouth—Epirubicin—prostate cancer	6.64e-05	0.000221	CcSEcCtD
Dipyridamole—Vertigo—Doxorubicin—prostate cancer	6.63e-05	0.00022	CcSEcCtD
Dipyridamole—Syncope—Doxorubicin—prostate cancer	6.62e-05	0.00022	CcSEcCtD
Dipyridamole—Urticaria—Prednisone—prostate cancer	6.61e-05	0.00022	CcSEcCtD
Dipyridamole—Pruritus—Capecitabine—prostate cancer	6.61e-05	0.00022	CcSEcCtD
Dipyridamole—Diarrhoea—Docetaxel—prostate cancer	6.6e-05	0.000219	CcSEcCtD
Dipyridamole—Abdominal pain—Prednisone—prostate cancer	6.58e-05	0.000219	CcSEcCtD
Dipyridamole—Palpitations—Doxorubicin—prostate cancer	6.52e-05	0.000217	CcSEcCtD
Dipyridamole—Anaphylactic shock—Epirubicin—prostate cancer	6.51e-05	0.000216	CcSEcCtD
Dipyridamole—Oedema—Epirubicin—prostate cancer	6.51e-05	0.000216	CcSEcCtD
Dipyridamole—Loss of consciousness—Doxorubicin—prostate cancer	6.49e-05	0.000215	CcSEcCtD
Dipyridamole—Cough—Doxorubicin—prostate cancer	6.44e-05	0.000214	CcSEcCtD
Dipyridamole—Shock—Epirubicin—prostate cancer	6.41e-05	0.000213	CcSEcCtD
Dipyridamole—Convulsion—Doxorubicin—prostate cancer	6.39e-05	0.000212	CcSEcCtD
Dipyridamole—Diarrhoea—Capecitabine—prostate cancer	6.39e-05	0.000212	CcSEcCtD
Dipyridamole—Nervous system disorder—Epirubicin—prostate cancer	6.38e-05	0.000212	CcSEcCtD
Dipyridamole—Dizziness—Docetaxel—prostate cancer	6.38e-05	0.000212	CcSEcCtD
Dipyridamole—Thrombocytopenia—Epirubicin—prostate cancer	6.37e-05	0.000212	CcSEcCtD
Dipyridamole—Hypertension—Doxorubicin—prostate cancer	6.37e-05	0.000212	CcSEcCtD
Dipyridamole—Tachycardia—Epirubicin—prostate cancer	6.35e-05	0.000211	CcSEcCtD
Dipyridamole—Skin disorder—Epirubicin—prostate cancer	6.32e-05	0.00021	CcSEcCtD
Dipyridamole—Hyperhidrosis—Epirubicin—prostate cancer	6.29e-05	0.000209	CcSEcCtD
Dipyridamole—Myalgia—Doxorubicin—prostate cancer	6.28e-05	0.000209	CcSEcCtD
Dipyridamole—Chest pain—Doxorubicin—prostate cancer	6.28e-05	0.000209	CcSEcCtD
Dipyridamole—Arthralgia—Doxorubicin—prostate cancer	6.28e-05	0.000209	CcSEcCtD
Dipyridamole—Anxiety—Doxorubicin—prostate cancer	6.26e-05	0.000208	CcSEcCtD
Dipyridamole—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	6.24e-05	0.000207	CcSEcCtD
Dipyridamole—Discomfort—Doxorubicin—prostate cancer	6.21e-05	0.000206	CcSEcCtD
Dipyridamole—Dizziness—Capecitabine—prostate cancer	6.18e-05	0.000205	CcSEcCtD
Dipyridamole—Dry mouth—Doxorubicin—prostate cancer	6.15e-05	0.000204	CcSEcCtD
Dipyridamole—Vomiting—Docetaxel—prostate cancer	6.14e-05	0.000204	CcSEcCtD
Dipyridamole—Hypersensitivity—Prednisone—prostate cancer	6.13e-05	0.000204	CcSEcCtD
Dipyridamole—Rash—Docetaxel—prostate cancer	6.09e-05	0.000202	CcSEcCtD
Dipyridamole—Hypotension—Epirubicin—prostate cancer	6.08e-05	0.000202	CcSEcCtD
Dipyridamole—Dermatitis—Docetaxel—prostate cancer	6.08e-05	0.000202	CcSEcCtD
Dipyridamole—Headache—Docetaxel—prostate cancer	6.05e-05	0.000201	CcSEcCtD
Dipyridamole—Anaphylactic shock—Doxorubicin—prostate cancer	6.02e-05	0.0002	CcSEcCtD
Dipyridamole—Oedema—Doxorubicin—prostate cancer	6.02e-05	0.0002	CcSEcCtD
Dipyridamole—Asthenia—Prednisone—prostate cancer	5.97e-05	0.000198	CcSEcCtD
Dipyridamole—Vomiting—Capecitabine—prostate cancer	5.94e-05	0.000197	CcSEcCtD
Dipyridamole—Musculoskeletal discomfort—Epirubicin—prostate cancer	5.93e-05	0.000197	CcSEcCtD
Dipyridamole—Shock—Doxorubicin—prostate cancer	5.93e-05	0.000197	CcSEcCtD
Dipyridamole—Nervous system disorder—Doxorubicin—prostate cancer	5.91e-05	0.000196	CcSEcCtD
Dipyridamole—Thrombocytopenia—Doxorubicin—prostate cancer	5.9e-05	0.000196	CcSEcCtD
Dipyridamole—Rash—Capecitabine—prostate cancer	5.89e-05	0.000196	CcSEcCtD
Dipyridamole—Pruritus—Prednisone—prostate cancer	5.89e-05	0.000196	CcSEcCtD
Dipyridamole—Dermatitis—Capecitabine—prostate cancer	5.89e-05	0.000196	CcSEcCtD
Dipyridamole—Tachycardia—Doxorubicin—prostate cancer	5.88e-05	0.000195	CcSEcCtD
Dipyridamole—Headache—Capecitabine—prostate cancer	5.85e-05	0.000194	CcSEcCtD
Dipyridamole—Skin disorder—Doxorubicin—prostate cancer	5.85e-05	0.000194	CcSEcCtD
Dipyridamole—Paraesthesia—Epirubicin—prostate cancer	5.85e-05	0.000194	CcSEcCtD
Dipyridamole—Hyperhidrosis—Doxorubicin—prostate cancer	5.82e-05	0.000193	CcSEcCtD
Dipyridamole—Dyspnoea—Epirubicin—prostate cancer	5.8e-05	0.000193	CcSEcCtD
Dipyridamole—Somnolence—Epirubicin—prostate cancer	5.79e-05	0.000192	CcSEcCtD
Dipyridamole—Nausea—Docetaxel—prostate cancer	5.73e-05	0.00019	CcSEcCtD
Dipyridamole—Dyspepsia—Epirubicin—prostate cancer	5.73e-05	0.00019	CcSEcCtD
Dipyridamole—Diarrhoea—Prednisone—prostate cancer	5.7e-05	0.000189	CcSEcCtD
Dipyridamole—Hypotension—Doxorubicin—prostate cancer	5.63e-05	0.000187	CcSEcCtD
Dipyridamole—Gastrointestinal disorder—Epirubicin—prostate cancer	5.62e-05	0.000187	CcSEcCtD
Dipyridamole—Fatigue—Epirubicin—prostate cancer	5.61e-05	0.000186	CcSEcCtD
Dipyridamole—Pain—Epirubicin—prostate cancer	5.57e-05	0.000185	CcSEcCtD
Dipyridamole—Nausea—Capecitabine—prostate cancer	5.55e-05	0.000184	CcSEcCtD
Dipyridamole—Dizziness—Prednisone—prostate cancer	5.5e-05	0.000183	CcSEcCtD
Dipyridamole—Musculoskeletal discomfort—Doxorubicin—prostate cancer	5.49e-05	0.000182	CcSEcCtD
Dipyridamole—Paraesthesia—Doxorubicin—prostate cancer	5.41e-05	0.00018	CcSEcCtD
Dipyridamole—Dyspnoea—Doxorubicin—prostate cancer	5.37e-05	0.000178	CcSEcCtD
Dipyridamole—Feeling abnormal—Epirubicin—prostate cancer	5.36e-05	0.000178	CcSEcCtD
Dipyridamole—Somnolence—Doxorubicin—prostate cancer	5.36e-05	0.000178	CcSEcCtD
Dipyridamole—Gastrointestinal pain—Epirubicin—prostate cancer	5.32e-05	0.000177	CcSEcCtD
Dipyridamole—Dyspepsia—Doxorubicin—prostate cancer	5.3e-05	0.000176	CcSEcCtD
Dipyridamole—Vomiting—Prednisone—prostate cancer	5.29e-05	0.000176	CcSEcCtD
Dipyridamole—Rash—Prednisone—prostate cancer	5.25e-05	0.000174	CcSEcCtD
Dipyridamole—Dermatitis—Prednisone—prostate cancer	5.24e-05	0.000174	CcSEcCtD
Dipyridamole—Headache—Prednisone—prostate cancer	5.21e-05	0.000173	CcSEcCtD
Dipyridamole—Gastrointestinal disorder—Doxorubicin—prostate cancer	5.2e-05	0.000173	CcSEcCtD
Dipyridamole—Fatigue—Doxorubicin—prostate cancer	5.19e-05	0.000172	CcSEcCtD
Dipyridamole—Urticaria—Epirubicin—prostate cancer	5.17e-05	0.000172	CcSEcCtD
Dipyridamole—Pain—Doxorubicin—prostate cancer	5.15e-05	0.000171	CcSEcCtD
Dipyridamole—Abdominal pain—Epirubicin—prostate cancer	5.15e-05	0.000171	CcSEcCtD
Dipyridamole—Feeling abnormal—Doxorubicin—prostate cancer	4.96e-05	0.000165	CcSEcCtD
Dipyridamole—Nausea—Prednisone—prostate cancer	4.94e-05	0.000164	CcSEcCtD
Dipyridamole—Gastrointestinal pain—Doxorubicin—prostate cancer	4.93e-05	0.000164	CcSEcCtD
Dipyridamole—Hypersensitivity—Epirubicin—prostate cancer	4.8e-05	0.000159	CcSEcCtD
Dipyridamole—Urticaria—Doxorubicin—prostate cancer	4.79e-05	0.000159	CcSEcCtD
Dipyridamole—Abdominal pain—Doxorubicin—prostate cancer	4.76e-05	0.000158	CcSEcCtD
Dipyridamole—Asthenia—Epirubicin—prostate cancer	4.67e-05	0.000155	CcSEcCtD
Dipyridamole—Pruritus—Epirubicin—prostate cancer	4.61e-05	0.000153	CcSEcCtD
Dipyridamole—Diarrhoea—Epirubicin—prostate cancer	4.45e-05	0.000148	CcSEcCtD
Dipyridamole—Hypersensitivity—Doxorubicin—prostate cancer	4.44e-05	0.000147	CcSEcCtD
Dipyridamole—Asthenia—Doxorubicin—prostate cancer	4.32e-05	0.000144	CcSEcCtD
Dipyridamole—Dizziness—Epirubicin—prostate cancer	4.31e-05	0.000143	CcSEcCtD
Dipyridamole—Pruritus—Doxorubicin—prostate cancer	4.26e-05	0.000142	CcSEcCtD
Dipyridamole—Vomiting—Epirubicin—prostate cancer	4.14e-05	0.000137	CcSEcCtD
Dipyridamole—Diarrhoea—Doxorubicin—prostate cancer	4.12e-05	0.000137	CcSEcCtD
Dipyridamole—Rash—Epirubicin—prostate cancer	4.1e-05	0.000136	CcSEcCtD
Dipyridamole—Dermatitis—Epirubicin—prostate cancer	4.1e-05	0.000136	CcSEcCtD
Dipyridamole—Headache—Epirubicin—prostate cancer	4.08e-05	0.000135	CcSEcCtD
Dipyridamole—Dizziness—Doxorubicin—prostate cancer	3.98e-05	0.000132	CcSEcCtD
Dipyridamole—Nausea—Epirubicin—prostate cancer	3.87e-05	0.000128	CcSEcCtD
Dipyridamole—Vomiting—Doxorubicin—prostate cancer	3.83e-05	0.000127	CcSEcCtD
Dipyridamole—Rash—Doxorubicin—prostate cancer	3.8e-05	0.000126	CcSEcCtD
Dipyridamole—Dermatitis—Doxorubicin—prostate cancer	3.79e-05	0.000126	CcSEcCtD
Dipyridamole—Headache—Doxorubicin—prostate cancer	3.77e-05	0.000125	CcSEcCtD
Dipyridamole—Nausea—Doxorubicin—prostate cancer	3.58e-05	0.000119	CcSEcCtD
Dipyridamole—PDE3A—Signaling by GPCR—PIK3CA—prostate cancer	4.27e-06	1.52e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—CDKN1B—prostate cancer	4.27e-06	1.52e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—PIK3CB—prostate cancer	4.26e-06	1.52e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Immune System—STAT3—prostate cancer	4.26e-06	1.52e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—MDM2—prostate cancer	4.26e-06	1.52e-05	CbGpPWpGaD
Dipyridamole—PDE11A—Signaling Pathways—IL6—prostate cancer	4.26e-06	1.52e-05	CbGpPWpGaD
Dipyridamole—PDE7A—Signaling Pathways—IL6—prostate cancer	4.26e-06	1.52e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—IGF1—prostate cancer	4.26e-06	1.52e-05	CbGpPWpGaD
Dipyridamole—PDE6G—Signaling Pathways—TP53—prostate cancer	4.25e-06	1.52e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling by GPCR—EGFR—prostate cancer	4.23e-06	1.51e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Immune System—EGFR—prostate cancer	4.23e-06	1.51e-05	CbGpPWpGaD
Dipyridamole—PDE7B—Signaling Pathways—AKT1—prostate cancer	4.22e-06	1.51e-05	CbGpPWpGaD
Dipyridamole—PDE3B—GPCR downstream signaling—AKT1—prostate cancer	4.22e-06	1.51e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—NOS3—prostate cancer	4.22e-06	1.5e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—ERBB2—prostate cancer	4.2e-06	1.5e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—prostate cancer	4.19e-06	1.5e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—EP300—prostate cancer	4.19e-06	1.49e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—CASP3—prostate cancer	4.18e-06	1.49e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—IL2—prostate cancer	4.18e-06	1.49e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—SLC22A1—prostate cancer	4.16e-06	1.49e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Transmembrane transport of small molecules—PPARA—prostate cancer	4.16e-06	1.48e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling by GPCR—IL6—prostate cancer	4.15e-06	1.48e-05	CbGpPWpGaD
Dipyridamole—PDE10A—Signaling Pathways—TP53—prostate cancer	4.14e-06	1.48e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—PIK3CB—prostate cancer	4.14e-06	1.48e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—MAP2K1—prostate cancer	4.11e-06	1.47e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—JAK2—prostate cancer	4.1e-06	1.46e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—CXCL8—prostate cancer	4.09e-06	1.46e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—PIK3CD—prostate cancer	4.09e-06	1.46e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—SRC—prostate cancer	4.08e-06	1.45e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—CCND1—prostate cancer	4.07e-06	1.45e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—SULT2A1—prostate cancer	4.06e-06	1.45e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—prostate cancer	4.06e-06	1.45e-05	CbGpPWpGaD
Dipyridamole—PDE1B—GPCR downstream signaling—PIK3CA—prostate cancer	4.05e-06	1.44e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—SERPINE1—prostate cancer	4.04e-06	1.44e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—CTNNB1—prostate cancer	4.03e-06	1.44e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Metabolism—PTEN—prostate cancer	4.02e-06	1.43e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling by GPCR—PIK3CA—prostate cancer	4.02e-06	1.43e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—MDM2—prostate cancer	4e-06	1.43e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling by GPCR—KRAS—prostate cancer	4e-06	1.43e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Immune System—KRAS—prostate cancer	4e-06	1.42e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—CDKN1B—prostate cancer	4e-06	1.42e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—MED12—prostate cancer	3.99e-06	1.42e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Disease—MYC—prostate cancer	3.99e-06	1.42e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Disease—MYC—prostate cancer	3.99e-06	1.42e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Disease—TGFB1—prostate cancer	3.98e-06	1.42e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Disease—TGFB1—prostate cancer	3.98e-06	1.42e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—CXCL8—prostate cancer	3.98e-06	1.42e-05	CbGpPWpGaD
Dipyridamole—ABCC4—Hemostasis—AKT1—prostate cancer	3.96e-06	1.41e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—GNG5—prostate cancer	3.96e-06	1.41e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—MMP9—prostate cancer	3.95e-06	1.41e-05	CbGpPWpGaD
Dipyridamole—PDE4A—GPCR downstream signaling—AKT1—prostate cancer	3.95e-06	1.41e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—ERBB2—prostate cancer	3.95e-06	1.41e-05	CbGpPWpGaD
Dipyridamole—PDE1C—Signaling Pathways—IL6—prostate cancer	3.95e-06	1.41e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—CDKN1A—prostate cancer	3.94e-06	1.4e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—STAT3—prostate cancer	3.93e-06	1.4e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—PTEN—prostate cancer	3.93e-06	1.4e-05	CbGpPWpGaD
Dipyridamole—PDE11A—Signaling Pathways—AKT1—prostate cancer	3.93e-06	1.4e-05	CbGpPWpGaD
Dipyridamole—PDE7A—Signaling Pathways—AKT1—prostate cancer	3.93e-06	1.4e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—CASP3—prostate cancer	3.92e-06	1.4e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—FGF2—prostate cancer	3.91e-06	1.39e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—IL2—prostate cancer	3.91e-06	1.39e-05	CbGpPWpGaD
Dipyridamole—ADA—Metabolism—PIK3CA—prostate cancer	3.91e-06	1.39e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Disease—EGFR—prostate cancer	3.91e-06	1.39e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Disease—EGFR—prostate cancer	3.91e-06	1.39e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—PIK3CB—prostate cancer	3.89e-06	1.39e-05	CbGpPWpGaD
Dipyridamole—PDE6G—Signaling Pathways—IL6—prostate cancer	3.89e-06	1.39e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling by GPCR—IL6—prostate cancer	3.89e-06	1.39e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—CDKN1B—prostate cancer	3.89e-06	1.39e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Immune System—EGFR—prostate cancer	3.87e-06	1.38e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—NOS3—prostate cancer	3.86e-06	1.38e-05	CbGpPWpGaD
Dipyridamole—PDE3A—GPCR downstream signaling—AKT1—prostate cancer	3.84e-06	1.37e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Metabolism—EP300—prostate cancer	3.84e-06	1.37e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling by GPCR—AKT1—prostate cancer	3.83e-06	1.37e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—NCOA3—prostate cancer	3.82e-06	1.36e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—CCND1—prostate cancer	3.81e-06	1.36e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—CASP3—prostate cancer	3.81e-06	1.36e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—IL2—prostate cancer	3.8e-06	1.36e-05	CbGpPWpGaD
Dipyridamole—PDE10A—Signaling Pathways—IL6—prostate cancer	3.79e-06	1.35e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling by GPCR—IL6—prostate cancer	3.78e-06	1.35e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—CTNNB1—prostate cancer	3.77e-06	1.35e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—JAK2—prostate cancer	3.75e-06	1.34e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—EP300—prostate cancer	3.75e-06	1.34e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—CXCL8—prostate cancer	3.74e-06	1.33e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—CCND1—prostate cancer	3.71e-06	1.32e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—MMP9—prostate cancer	3.7e-06	1.32e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Disease—KRAS—prostate cancer	3.69e-06	1.32e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Disease—KRAS—prostate cancer	3.69e-06	1.32e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—CDKN1A—prostate cancer	3.69e-06	1.31e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—PTEN—prostate cancer	3.68e-06	1.31e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling by GPCR—PIK3CA—prostate cancer	3.67e-06	1.31e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—CTNNB1—prostate cancer	3.67e-06	1.31e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Immune System—PIK3CA—prostate cancer	3.67e-06	1.31e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—MDM2—prostate cancer	3.66e-06	1.31e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Immune System—KRAS—prostate cancer	3.65e-06	1.3e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—CDKN1B—prostate cancer	3.65e-06	1.3e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—MYC—prostate cancer	3.65e-06	1.3e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—SRC—prostate cancer	3.64e-06	1.3e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—TGFB1—prostate cancer	3.64e-06	1.3e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—HPGDS—prostate cancer	3.64e-06	1.3e-05	CbGpPWpGaD
Dipyridamole—PDE1C—Signaling Pathways—AKT1—prostate cancer	3.64e-06	1.3e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—CYP2C19—prostate cancer	3.62e-06	1.29e-05	CbGpPWpGaD
Dipyridamole—PDE1A—GPCR downstream signaling—AKT1—prostate cancer	3.61e-06	1.29e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—ERBB2—prostate cancer	3.61e-06	1.29e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—MMP9—prostate cancer	3.6e-06	1.28e-05	CbGpPWpGaD
Dipyridamole—PDE6G—Signaling Pathways—AKT1—prostate cancer	3.59e-06	1.28e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling by GPCR—AKT1—prostate cancer	3.59e-06	1.28e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—CDKN1A—prostate cancer	3.59e-06	1.28e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—CASP3—prostate cancer	3.58e-06	1.28e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—PTEN—prostate cancer	3.58e-06	1.28e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—IL2—prostate cancer	3.58e-06	1.28e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—EGFR—prostate cancer	3.57e-06	1.27e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—PIK3CB—prostate cancer	3.56e-06	1.27e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling by GPCR—IL6—prostate cancer	3.56e-06	1.27e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—VEGFA—prostate cancer	3.55e-06	1.27e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—GSTT1—prostate cancer	3.53e-06	1.26e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—ACHE—prostate cancer	3.53e-06	1.26e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—STAT3—prostate cancer	3.51e-06	1.25e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—EP300—prostate cancer	3.51e-06	1.25e-05	CbGpPWpGaD
Dipyridamole—PDE10A—Signaling Pathways—AKT1—prostate cancer	3.5e-06	1.25e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling by GPCR—AKT1—prostate cancer	3.49e-06	1.24e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—CYP2A6—prostate cancer	3.49e-06	1.24e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—CCND1—prostate cancer	3.49e-06	1.24e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—CTNNB1—prostate cancer	3.45e-06	1.23e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—prostate cancer	3.43e-06	1.22e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—CXCL8—prostate cancer	3.42e-06	1.22e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—EP300—prostate cancer	3.41e-06	1.22e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—SRC—prostate cancer	3.41e-06	1.22e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—AKR1C3—prostate cancer	3.4e-06	1.21e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Disease—PIK3CA—prostate cancer	3.39e-06	1.21e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Disease—PIK3CA—prostate cancer	3.39e-06	1.21e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—MMP9—prostate cancer	3.38e-06	1.21e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—PRKACB—prostate cancer	3.38e-06	1.2e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—KRAS—prostate cancer	3.37e-06	1.2e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—CDKN1A—prostate cancer	3.37e-06	1.2e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—PTEN—prostate cancer	3.36e-06	1.2e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Immune System—PIK3CA—prostate cancer	3.36e-06	1.2e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—CYP17A1—prostate cancer	3.34e-06	1.19e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—CDKN1B—prostate cancer	3.34e-06	1.19e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—VEGFA—prostate cancer	3.32e-06	1.18e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—SRC—prostate cancer	3.32e-06	1.18e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Transmembrane transport of small molecules—CREBBP—prostate cancer	3.31e-06	1.18e-05	CbGpPWpGaD
Dipyridamole—PDE1B—GPCR downstream signaling—AKT1—prostate cancer	3.31e-06	1.18e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—STAT3—prostate cancer	3.29e-06	1.17e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling by GPCR—AKT1—prostate cancer	3.28e-06	1.17e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—CASP3—prostate cancer	3.28e-06	1.17e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—IL2—prostate cancer	3.27e-06	1.17e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—MYC—prostate cancer	3.27e-06	1.16e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—TGFB1—prostate cancer	3.26e-06	1.16e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling by GPCR—IL6—prostate cancer	3.25e-06	1.16e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Immune System—IL6—prostate cancer	3.25e-06	1.16e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—VEGFA—prostate cancer	3.23e-06	1.15e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—EP300—prostate cancer	3.21e-06	1.14e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—STAT3—prostate cancer	3.2e-06	1.14e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—EGFR—prostate cancer	3.19e-06	1.14e-05	CbGpPWpGaD
Dipyridamole—ADA—Metabolism—AKT1—prostate cancer	3.19e-06	1.14e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—CCND1—prostate cancer	3.19e-06	1.14e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—NCOA2—prostate cancer	3.18e-06	1.14e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—CTNNB1—prostate cancer	3.16e-06	1.13e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—SRC—prostate cancer	3.12e-06	1.11e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—PIK3CA—prostate cancer	3.1e-06	1.11e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—MMP9—prostate cancer	3.1e-06	1.1e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—CDKN1A—prostate cancer	3.08e-06	1.1e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—PTEN—prostate cancer	3.08e-06	1.1e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—MYC—prostate cancer	3.06e-06	1.09e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—TGFB1—prostate cancer	3.05e-06	1.09e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—VEGFA—prostate cancer	3.04e-06	1.08e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—SLC5A5—prostate cancer	3.04e-06	1.08e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—KRAS—prostate cancer	3.02e-06	1.08e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—STAT3—prostate cancer	3.01e-06	1.07e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling by GPCR—AKT1—prostate cancer	3e-06	1.07e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Disease—IL6—prostate cancer	3e-06	1.07e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Disease—IL6—prostate cancer	3e-06	1.07e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Immune System—AKT1—prostate cancer	3e-06	1.07e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—EGFR—prostate cancer	2.99e-06	1.07e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—MYC—prostate cancer	2.97e-06	1.06e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Immune System—IL6—prostate cancer	2.97e-06	1.06e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—CYP2E1—prostate cancer	2.97e-06	1.06e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—TGFB1—prostate cancer	2.97e-06	1.06e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—EP300—prostate cancer	2.93e-06	1.05e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—NQO1—prostate cancer	2.93e-06	1.05e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—EGFR—prostate cancer	2.91e-06	1.04e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—TH—prostate cancer	2.89e-06	1.03e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—CYP3A4—prostate cancer	2.86e-06	1.02e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—SRC—prostate cancer	2.85e-06	1.02e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Metabolism—PIK3CA—prostate cancer	2.84e-06	1.01e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—KRAS—prostate cancer	2.82e-06	1.01e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—CYP1B1—prostate cancer	2.81e-06	1e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—MYC—prostate cancer	2.8e-06	9.97e-06	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—TGFB1—prostate cancer	2.79e-06	9.95e-06	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—VEGFA—prostate cancer	2.78e-06	9.91e-06	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—PIK3CA—prostate cancer	2.77e-06	9.88e-06	CbGpPWpGaD
Dipyridamole—PDE1A—Disease—AKT1—prostate cancer	2.77e-06	9.87e-06	CbGpPWpGaD
Dipyridamole—ABCC5—Disease—AKT1—prostate cancer	2.77e-06	9.87e-06	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—STAT3—prostate cancer	2.75e-06	9.81e-06	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—KRAS—prostate cancer	2.75e-06	9.8e-06	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—IL6—prostate cancer	2.75e-06	9.79e-06	CbGpPWpGaD
Dipyridamole—PDE1B—Immune System—AKT1—prostate cancer	2.74e-06	9.78e-06	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—EGFR—prostate cancer	2.73e-06	9.75e-06	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—GGT1—prostate cancer	2.72e-06	9.72e-06	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—NCOA1—prostate cancer	2.68e-06	9.57e-06	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—TP53—prostate cancer	2.68e-06	9.56e-06	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—CYP19A1—prostate cancer	2.65e-06	9.43e-06	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—PIK3CA—prostate cancer	2.6e-06	9.25e-06	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—KRAS—prostate cancer	2.58e-06	9.21e-06	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—MYC—prostate cancer	2.56e-06	9.12e-06	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—RXRA—prostate cancer	2.55e-06	9.1e-06	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—TGFB1—prostate cancer	2.55e-06	9.1e-06	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—AKT1—prostate cancer	2.53e-06	9.03e-06	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—PIK3CA—prostate cancer	2.52e-06	9e-06	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—TP53—prostate cancer	2.51e-06	8.95e-06	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—EGFR—prostate cancer	2.5e-06	8.92e-06	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—COMT—prostate cancer	2.46e-06	8.77e-06	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—IL6—prostate cancer	2.45e-06	8.75e-06	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—GSTP1—prostate cancer	2.45e-06	8.73e-06	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—TP53—prostate cancer	2.44e-06	8.71e-06	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—ITPR1—prostate cancer	2.41e-06	8.59e-06	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—PIK3CA—prostate cancer	2.37e-06	8.46e-06	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—KRAS—prostate cancer	2.36e-06	8.43e-06	CbGpPWpGaD
Dipyridamole—ABCC5—Metabolism—AKT1—prostate cancer	2.32e-06	8.27e-06	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—IL6—prostate cancer	2.3e-06	8.19e-06	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—TP53—prostate cancer	2.3e-06	8.19e-06	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—TYMS—prostate cancer	2.28e-06	8.11e-06	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—AKT1—prostate cancer	2.26e-06	8.07e-06	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—GSTM1—prostate cancer	2.25e-06	8.02e-06	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—IL6—prostate cancer	2.24e-06	7.97e-06	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—LPL—prostate cancer	2.21e-06	7.87e-06	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—PIK3CA—prostate cancer	2.17e-06	7.74e-06	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—CYP1A1—prostate cancer	2.13e-06	7.6e-06	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—AKT1—prostate cancer	2.12e-06	7.56e-06	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—ERCC2—prostate cancer	2.11e-06	7.54e-06	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—IL6—prostate cancer	2.1e-06	7.5e-06	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—TP53—prostate cancer	2.1e-06	7.49e-06	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—AKT1—prostate cancer	2.06e-06	7.35e-06	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—MTHFR—prostate cancer	1.99e-06	7.09e-06	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—PPARA—prostate cancer	1.95e-06	6.95e-06	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—AKT1—prostate cancer	1.94e-06	6.91e-06	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—IL6—prostate cancer	1.92e-06	6.86e-06	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—CAV1—prostate cancer	1.83e-06	6.54e-06	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—AKT1—prostate cancer	1.77e-06	6.32e-06	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—PIK3CG—prostate cancer	1.67e-06	5.96e-06	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—INS—prostate cancer	1.58e-06	5.64e-06	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—CREBBP—prostate cancer	1.55e-06	5.52e-06	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—PIK3CD—prostate cancer	1.47e-06	5.24e-06	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—NOS3—prostate cancer	1.39e-06	4.94e-06	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—PIK3CB—prostate cancer	1.28e-06	4.56e-06	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—PTGS2—prostate cancer	1.27e-06	4.52e-06	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—PTEN—prostate cancer	1.11e-06	3.94e-06	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—EP300—prostate cancer	1.05e-06	3.76e-06	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—PIK3CA—prostate cancer	7.8e-07	2.78e-06	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—AKT1—prostate cancer	6.37e-07	2.27e-06	CbGpPWpGaD
